Stockscreener 앱 받기
1.985
1.97%
-0.045
전일 마감가:
$2.03
열려 있는:
$2.04
하루 거래량:
43,421
Relative Volume:
0.16
시가총액:
$50.14M
수익:
-
순이익/손실:
$-13.76M
주가수익비율:
-2.1344
EPS:
-0.93
순현금흐름:
-
1주 성능:
-5.69%
1개월 성능:
-17.08%
6개월 성능:
+82.57%
1년 성능:
+152.63%
1일 변동 폭
$1.98
$2.04
1주일 범위
$1.9202
$2.14
52주 변동 폭
$0.512
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
NRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.985 | 50.14M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.72 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.49 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.67 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.97 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.72 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
What makes NeuroSense Therapeutics Ltd. Equity Warrant stock price move sharplyTrade Ready Signal - Newser
What makes NeuroSense Therapeutics Ltd. stock price move sharplyMassive Profit Potential - Newser
How NeuroSense Therapeutics Ltd. stock performs during market volatilityProven Trading Plan - Newser
Why NeuroSense Therapeutics Ltd. Equity Warrant stock attracts strong analyst attentionExpert Backed Predictions - Newser
How NeuroSense Therapeutics Ltd. Equity Warrant stock performs during market volatilityGrowth Optimized Stock Radar - Newser
Why NeuroSense Therapeutics Ltd. stock attracts strong analyst attentionHigh Return Intraday Picks - Newser
D. Boral Capital Reaffirms Buy Rating for NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
NeuroSense Therapeutics Releases Q2 2025 Corporate Update - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading 0.5% Higher – Here’s What Happened - Defense World
NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval - TipRanks
NRSN: Health Canada Meeting Advances PrimeC Toward Expedited ALS Approval - Stock Titan
NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Tuesday - Defense World
Why It Makes Sense To Keep An Eye On NeuroSense Therapeutics - RTTNews
NeuroSense Stock Soars 10.33% on ALS Treatment Commercialization Plans - AInvest
Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
Top Nasdaq Companies by Market Cap Ranked by Kalkine - Kalkine Media
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 1.2% – Here’s What Happened - Defense World
Citadel Advisors LLC Buys 219,717 Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
NRSNNeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - mx.advfn.com
NRSN stock touches 52-week high at $1.65 amid robust gains - Investing.com
NRSN stock touches 52-week high at $1.52 amid growth optimism - Investing.com Australia
D. Boral Capital Begins Coverage on NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation - Nasdaq
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsNeuroSense Therapeutics (NASDAQ:NRSN) - Benzinga
Boral Capital starts NeuroSense stock with Buy, $14 target By Investing.com - Investing.com South Africa
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga
NeuroSense (NRSN) Receives Buy Rating with Promising Outlook | N - GuruFocus
Boral Capital starts NeuroSense stock with Buy, $14 target - Investing.com
Amyotrophic Lateral Sclerosis Market Set for Groundbreaking - openPR.com
NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch - TipRanks
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - Nasdaq
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - ADVFN
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - ADVFN
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World
NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow
Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com
Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PR Newswire
Neurosense Therapeutics Ltd (NRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
2.49%
자본화:
|
볼륨(24시간):